Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
|Podcasts|May 20, 2021
The Cutaneous Connection: Episode 23- Roundup of AAD VMX 2021
Author(s)Morgan Petronelli
In this episode, we take a look back at what happened at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), including exclusive interviews with two KOLs about their presentations regarding climate change and new data on biologics for psoriasis.
Advertisement
Advertisement
Related to this article
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.
Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
This review of the latest dermatological studies includes insights on stem cell therapies for skin rejuvenation, smoke exposure in HS, hair loss in pediatric IBD, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
2
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
3
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
4
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
5